

IN THE UNITED STATES PATENT AND TRADEM. OFF'

Patent Application of

Atty Dkt. 2752-24

MAERTENS et al

C# M#

Serial No. 09/686,964

Group Art Unit: 1641


Examiner: McCaa

Filed: October 12, 2000

Date: April 20, 2001

Title: IMPROVED IMMUNODIAGNOSTIC ASSAYS USING REDUCING AGENTS

Assistant Commissioner for Patents  
Washington, DC 20231



RECEIVED  
APR 24 2001  
TECH CENTER 1600/2900  
7/5/01  
4/24/01

Sir:

**RESPONSE/AMENDMENT/LETTER**

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

**Fees are attached as calculated below:**

Total effective claims after amendment 0 minus highest number  
previously paid for 20 (at least 20) = 0 x \$ 18.00 \$ 0.00

Independent claims after amendment 0 minus highest number  
previously paid for 3 (at least 3) = 0 x \$ 80.00 \$ 0.00

If proper multiple dependent claims now added for first time, add \$270.00 (ignore improper) \$ 0.00

Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$390.00/2 months; \$890.00/3 months) \$ 0.00

Terminal disclaimer enclosed, add \$ 110.00 \$ 0.00

☐ First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$710.00) \$ 0.00  
☐ Please enter the previously unentered, filed  
☐ Submission attached

**Subtotal \$ 0.00**

If "small entity," then enter half (1/2) of subtotal and subtract  
☐ Statement filed herewith -\$ 0.00

Rule 56 Information Disclosure Statement Filing Fee (\$180.00) \$ 0.00

Assignment Recording Fee (\$40.00) \$ 0.00

Other: Notice to Comply; copy of the following 10/12/00 papers: Prel. Amd.; Letter & paper Sequence 0.00  
Listing; IDS and PTO-1449; postcard receipt

**TOTAL FEE ENCLOSED \$ 0.00**

The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8<sup>th</sup> Floor  
Arlington, Virginia 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100  
BJS:ew

NIXON & VANDERHYE P.C.  
By Atty: B. J. Sadoff, Reg. No. 36,663

Signature: 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

**MAERTENS et al**

Serial No. **09/686,964**

Filed: **October 12, 2000**

For: **IMPROVED IMMUNODIAGNOSTIC ASSAYS USING  
REDUCING AGENTS**



Atty. Ref.: **2752-24**

Group: **1641**

Examiner: **McCaa**

RECEIVED  
#5/13  
4/24/01  
APR 24 2001

TECH CENTER 1600/2900

**April 20, 2001**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**RESPONSE**

Responsive to the Official Action dated March 20, 2001, the applicants respectfully submit the requisite Amendment, Statement and paper and computer-readable copies of the Sequence Listing were submitted October 12, 2000, with the original filing of the application. Copies of these documents are attached along with the undersigned's postcard receipt indicating these materials were received by the Patent Office on October 12, 2000. A further computer-readable copy of the Sequence Listing could be submitted upon further request by the Patent Office however the same is not believed to be required. A copy of the Notice of Comply attached to Office Action of March 20, 2001, is also attached. The Office is requested to contact the undersigned if anything further is required in this regard.

**MAERTENS et al**  
**Serial No. 09/686,964**

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_



**B. J. Sadoff**

Reg. No. 36,663

**BJS:eaw**

1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

Application No.: CE/1600/2001  
TECH. CH. 1600/2001  
APR 20 2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- O I P E**  
**APR 20 2001**  
**PATENT & TRADEMARK OFFICE**
- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
  - ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
  - ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
  - ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
  - ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
  - ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
  - ☐ 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216


For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**

**COPY**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Patent Application of

JAERTENS et al

Serial No. To Be Assigned

Filed: October 12, 2000

For: IMPROVED IMMUNODIAGNOSTIC  
ASSAYS USING REDUCING AGENTS

Atty. Ref.: 2551-48

Group:

Examiner:

**COPY**

\* \* \* \* \*

October 12, 2000

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

LETTER

The attached paper and computer readable copies of the Sequence Listing are the same. No new matter has been added.

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_

B.J. Sadoff  
Reg. No. 36,663

BJS:pd  
1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100